Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  122,319 results for ""Capecitabine""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

  • Authors : Gupta N; School of Medico-Legal Studies, National Forensic Sciences University, Sector 9, Gandhinagar, Gujarat, 382007, India.; Verma N

Subjects: Administration, Metronomic* ; Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage ; Capecitabine*/Capecitabine*/Capecitabine*/adverse effects

  • Source: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2024 Dec; Vol. 55 (4), pp. 1485-1497. Date of Electronic Publication: 2024 Aug 20.Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701).

  • Authors : Kimura Y; Department of Surgery, Kindai Nara Hospital, 1248-1 Otoda-cho, Ikoma, Nara, 630-0293, Japan. .; Sugimoto N

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/surgery

  • Source: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2025 Jan; Vol. 28 (1), pp. 112-121. Date Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.

  • Authors : Hata T; Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan. .; Uemura M

Subjects: Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage ; Capecitabine*/Capecitabine*/Capecitabine*/adverse effects ; Capecitabine*/Capecitabine*/Capecitabine*/therapeutic use XELOX

  • Source: Scientific reports [Sci Rep] 2024 Nov 02; Vol. 14 (1), pp. 26434. Date of Electronic Publication: 2024 Nov 02.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy.

  • Authors : Zhang Y; Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, P.R. China.; Li X

Subjects: Bevacizumab*/Bevacizumab*/Bevacizumab*/administration & dosage ; Bevacizumab*/Bevacizumab*/Bevacizumab*/therapeutic use ; Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage

  • Source: Anticancer research [Anticancer Res] 2025 Jan; Vol. 45 (1), pp. 399-404.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Folate-Mediated Targeting and Controlled Release: PLGA-Encapsulated Mesoporous Silica Nanoparticles Delivering Capecitabine to Pancreatic Tumor.

  • Authors : Tripathi AD; School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, India.; Labh Y

Subjects: Silicon Dioxide*/Silicon Dioxide*/Silicon Dioxide*/chemistry ; Nanoparticles*/Nanoparticles*/Nanoparticles*/chemistry ; Folic Acid*/Folic Acid*/Folic Acid*/chemistry

  • Source: ACS applied bio materials [ACS Appl Bio Mater] 2024 Dec 16; Vol. 7 (12), pp. 7838-7851. Date of Electronic Publication: 2024 Mar 26.Publisher: ACS Publications Country of Publication: United States NLM ID: 101729147 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

A sustainable RP-HPLC method for concurrent estimation of capecitabine and celecoxib in liposomal formulation: Greenness and whiteness appraisal.

  • Authors : Shewale RS; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Gandhinagar, Gujarat, India.; Gomte SS

Subjects: Celecoxib*/Celecoxib*/Celecoxib*/analysis ; Celecoxib*/Celecoxib*/Celecoxib*/administration & dosage ; Liposomes*

  • Source: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2024 Dec; Vol. 357 (12), pp. e2400632. Date of Electronic Publication: 2024 Sep 29.Publisher: Wiley-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 0330167 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.

  • Authors : File DM; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC.; Abdou Y

Subjects: Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage ; Capecitabine*/Capecitabine*/Capecitabine*/adverse effects ; Capecitabine*/Capecitabine*/Capecitabine*/therapeutic use

  • Source: Clinical breast cancer [Clin Breast Cancer] 2024 Dec; Vol. 24 (8), pp. 683-690. Date of Electronic Publication: 2024 Aug 08.Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Capecitabine mitigates cardiac allograft rejection via inhibition of TYMS-Mediated Th1 differentiation in mice.

  • Authors : Kong D; Nankai University School of Medicine, Tianjin, China; Department of Organ Transplantation, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, China

Subjects: Heart Transplantation* ; Graft Rejection*/Graft Rejection*/Graft Rejection*/prevention & control ; Graft Rejection*/Graft Rejection*/Graft Rejection*/immunology

  • Source: International immunopharmacology [Int Immunopharmacol] 2024 Nov 15; Vol. 141, pp. 112955. Date of Electronic Publication: 2024 Aug 20.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide.

  • Authors : Gao H; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.

Subjects: Temozolomide*/Temozolomide*/Temozolomide*/therapeutic use ; Temozolomide*/Temozolomide*/Temozolomide*/pharmacology ; Temozolomide*/Temozolomide*/Temozolomide*/administration & dosage

  • Source: BMC cancer [BMC Cancer] 2024 Nov 07; Vol. 24 (1), pp. 1362. Date of Electronic Publication: 2024 Nov 07.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Prognostic Nutritional Index is Related to All-Cause Mortality in Patients With Stage IV Colorectal Cancer Treated With Capecitabine: Single-Center 24-Month Observational Study in Vietnam.

Subjects: Capecitabine*/Capecitabine*/Capecitabine*/therapeutic use ; Capecitabine*/Capecitabine*/Capecitabine*/adverse effects ; Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage

  • Source: Journal of clinical laboratory analysis [J Clin Lab Anal] 2024 Nov; Vol. 38 (21), pp. e25112. Date of Electronic Publication: 2024 Oct 08.Publisher: Wiley Country of Publication: United States NLM ID: 8801384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2825

Record details

Read More Add to Saved list
×
  • 1-10 of  122,319 results for ""Capecitabine""